- Home
- BREA vs GLTO Comparison
BREA vs GLTO Comparison
Compare BREA & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- GLTO
- Stock Information
- Founded
- BREA 2022
- GLTO 2011
- Country
- BREA Ireland
- GLTO Denmark
- Employees
- BREA N/A
- GLTO N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- GLTO Health Care
- Exchange
- BREA Nasdaq
- GLTO Nasdaq
- Market Cap
- BREA 8.7M
- GLTO 6.5M
- IPO Year
- BREA 2023
- GLTO 2020
- Fundamental
- Price
- BREA $0.66
- GLTO $4.01
- Analyst Decision
- BREA
- GLTO Buy
- Analyst Count
- BREA 0
- GLTO 1
- Target Price
- BREA N/A
- GLTO $10.00
- AVG Volume (30 Days)
- BREA 4.3M
- GLTO 17.1K
- Earning Date
- BREA 01-03-2025
- GLTO 04-28-2025
- Dividend Yield
- BREA N/A
- GLTO N/A
- EPS Growth
- BREA N/A
- GLTO N/A
- EPS
- BREA N/A
- GLTO N/A
- Revenue
- BREA $2,872,101.00
- GLTO N/A
- Revenue This Year
- BREA N/A
- GLTO N/A
- Revenue Next Year
- BREA N/A
- GLTO N/A
- P/E Ratio
- BREA N/A
- GLTO N/A
- Revenue Growth
- BREA 2338.69
- GLTO N/A
- 52 Week Low
- BREA $0.50
- GLTO $3.76
- 52 Week High
- BREA $1.95
- GLTO $21.05
- Technical
- Relative Strength Index (RSI)
- BREA 49.12
- GLTO 37.21
- Support Level
- BREA $0.60
- GLTO $3.84
- Resistance Level
- BREA $0.77
- GLTO $4.38
- Average True Range (ATR)
- BREA 0.11
- GLTO 0.28
- MACD
- BREA 0.01
- GLTO -0.02
- Stochastic Oscillator
- BREA 10.76
- GLTO 23.15
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.